Literature DB >> 7632809

Comparison of scoring systems in primary myelodysplastic syndromes.

H Maschek1, R Gutzmer, H Choritz, A Georgii.   

Abstract

To compare the prognostic value of scoring systems in primary myelodysplastic syndromes (pMDS), four clinicohematological systems (Rennes, Bournemouth, Düsseldorf, Pavia) and the histopathological Hannover Scoring System were applied to 415 MDS patients from the Bone Marrow Registry of Hannover Medical School. According to the FAB classification, 180 patients (43%) were diagnosed as RA, 33 (8%) as RARS, 99 (24%) as RAEB, 36 (9%) as RAEBt, and 48 (12%) as CMMOL; 19 patients (4%) were not further classified (MDS.UC). All scoring systems revealed three or four groups of patients with significantly different survival times. The ranges and standard deviations in these groups were similar but high in all scoring systems. A good differentiation between short-term survivors (< 1 year survival time) and intermediate-term survivors (1-4 years) was possible with all tested scoring systems, but the differentiation between intermediate- and long-term survivors (> 4 years) was not distinctive enough. The problem of risk assessment in the single patient is furthermore elucidated by the values of specificity and sensitivity, which were relatively low in all scoring systems tested. Best results were yielded by the Bournemouth Score for long-term survivors and the Düsseldorf and Hannover Score for intermediate- and short-term survivors. Multivariate analysis of all parameters used in the scoring systems showed the highest negative impact on survival for increase of myeloblasts, anemia, myelofibrosis, high age of the patient, and abnormal localization of immature precursors (ALIPs). Therefore, the histopathological Hannover Scoring System is not only equal to clinicohematological risk assessment in pMDS, but also includes important independent prognostic parameters. Risk assessment for the individual low-risk MDS patient using only initial parameters may be rendered impossible due to the biological nature of pMDS. Therefore, sequential analysis is needed to elucidate random events which alter the prognosis.

Entities:  

Mesh:

Year:  1995        PMID: 7632809     DOI: 10.1007/bf01696616

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  29 in total

1.  Risk assessment in myelodysplastic syndromes: value of clinical, hematologic and bone marrow histologic findings at presentation.

Authors:  E Morra; M Lazzarino; A Castello; D Inverardi; A Coci; E P Alessandrino; E Brusamolino; P Bernasconi; E Orlandi; M Bonfichi
Journal:  Eur J Haematol       Date:  1990-08       Impact factor: 2.997

Review 2.  A guide to risk assessment in the primary myelodysplastic syndrome.

Authors:  G J Mufti
Journal:  Hematol Oncol Clin North Am       Date:  1992-06       Impact factor: 3.722

3.  Myelodysplastic syndromes: a scoring system with prognostic significance.

Authors:  G J Mufti; J R Stevens; D G Oscier; T J Hamblin; D Machin
Journal:  Br J Haematol       Date:  1985-03       Impact factor: 6.998

4.  Evidence for a multistep pathogenesis of a myelodysplastic syndrome.

Authors:  W H Raskind; N Tirumali; R Jacobson; J Singer; P J Fialkow
Journal:  Blood       Date:  1984-06       Impact factor: 22.113

5.  Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan.

Authors:  K Toyama; K Ohyashiki; Y Yoshida; T Abe; S Asano; H Hirai; K Hirashima; T Hotta; A Kuramoto; S Kuriya
Journal:  Leukemia       Date:  1993-04       Impact factor: 11.528

6.  Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndromes.

Authors:  G Lambertenghi-Deliliers; C Annaloro; A Oriani; D Soligo; E Pozzoli; E E Polli
Journal:  Ann Hematol       Date:  1993-02       Impact factor: 3.673

7.  Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis.

Authors:  H Maschek; V Kaloutsi; M Rodriguez-Kaiser; M Werner; H Choritz; K Mainzer; M Dietzfelbinger; A Georgii
Journal:  Ann Hematol       Date:  1993-03       Impact factor: 3.673

8.  The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations.

Authors:  G Tricot; M A Boogaerts; C De Wolf-Peeters; H Van den Berghe; R L Verwilghen
Journal:  Br J Haematol       Date:  1985-04       Impact factor: 6.998

9.  Long-term survivors in myelodysplastic syndromes: a report on 63 cases and comparison with short and intermediate survivors.

Authors:  E Wattel; B Hecquet; D Grahek; M Hebbar; P Morel; J L Lai; F Bauters; P Fenaux
Journal:  Leuk Res       Date:  1993-09       Impact factor: 3.156

10.  Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS.

Authors:  G Tricot; C De Wolf-Peeters; R Vlietinck; R L Verwilghen
Journal:  Br J Haematol       Date:  1984-10       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.